These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21186975)

  • 21. NMS after clozapine initiation.
    Skarpathiotakis M; Westreich N
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1101-2. PubMed ID: 16239854
    [No Abstract]   [Full Text] [Related]  

  • 22. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine-induced weight loss?
    Appiani F; Carroll BT; Muñoz C; Trecco J
    Ann Clin Psychiatry; 2011 Aug; 23(3):225. PubMed ID: 21808755
    [No Abstract]   [Full Text] [Related]  

  • 26. Olanzapine and haloperidol for residual symptoms.
    de Haan L; van Beveren N
    Am J Psychiatry; 2005 Jul; 162(7):1392-3; author reply 1393. PubMed ID: 15994737
    [No Abstract]   [Full Text] [Related]  

  • 27. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
    Kinon BJ; Volavka J; Stauffer V; Edwards SE; Liu-Seifert H; Chen L; Adams DH; Lindenmayer JP; McEvoy JP; Buckley PF; Lieberman JA; Meltzer HY; Wilson DR; Citrome L
    J Clin Psychopharmacol; 2008 Aug; 28(4):392-400. PubMed ID: 18626265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents.
    Wu SY; Liu CC; Hsieh MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1089-90. PubMed ID: 18407390
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.
    Hodgson R; Belgamwar R; Al-tawarah Y; MacKenzie G
    Hum Psychopharmacol; 2005 Mar; 20(2):141-7. PubMed ID: 15651052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia.
    Kishi T; Suzuki T; Sekiguchi H; Moriwaki M; Okuda A; Mekata T; Hattori M; Tsunoka T; Chekuri R; Musso GM; Fujita K; Iwata N
    Asian J Psychiatr; 2013 Feb; 6(1):86-7. PubMed ID: 23380329
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of treatment refractory schizophrenia.
    Morrison DP
    Br J Psychiatry Suppl; 1996 Dec; (31):15-20. PubMed ID: 8968651
    [No Abstract]   [Full Text] [Related]  

  • 32. Clozapine rechallenge in refractory schizophrenia.
    Eseonu C; Carlson J
    Am J Psychiatry; 2010 May; 167(5):602-3. PubMed ID: 20439404
    [No Abstract]   [Full Text] [Related]  

  • 33. High-dose olanzapine versus clozapine.
    Mattes JA
    J Clin Psychiatry; 2008 Oct; 69(10):1660; author reply 1660-1. PubMed ID: 19192450
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
    Danilov DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):48-55. PubMed ID: 20517226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 37. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.
    Gunes A; Melkersson KI; Scordo MG; Dahl ML
    J Clin Psychopharmacol; 2009 Feb; 29(1):65-8. PubMed ID: 19142110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.
    Carrizo E; Fernández V; Quintero J; Connell L; Rodríguez Z; Mosquera M; Acosta A; Baptista T
    Schizophr Res; 2008 Aug; 103(1-3):83-93. PubMed ID: 18436434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 40. Olanzapine in adolescents with schizophrenia who manifest suicidal behaviour.
    De Giacomo A; Lozito V; Portoghese C
    Early Interv Psychiatry; 2008 May; 2(2):114-5. PubMed ID: 21352142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.